Under the technology agreement Activiomics will use its mass spectrometry-based TIQUAS platform to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.
Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.
The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.
Kinaxo Biotechnologies and Bayer Vital announced that they are collaborating to identify novel cancer treatment biomarkers.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.